Current approaches to management of depression in Parkinson's Disease

Journal of Clinical Neuroscience

Volumn 12, Issue 7, 2005, Pages 739-743

  Vajda, F J E ^a   Solinas, C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antidepressant side effects; Antidepressants; Depression; Parkinson's disease; SSRI; Tricyclic antidepressant

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIPARKINSON AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEVODOPA; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PETHIDINE; PRAMIPEXOLE; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; AKATHISIA; ANTICHOLINERGIC EFFECT; AUTOMUTILATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERHIDROSIS; HYPERREFLEXIA; HYPERTENSION; HYPERTENSIVE CRISIS; INSOMNIA; META ANALYSIS; MOTOR DYSFUNCTION; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; PUPIL DISEASE; RESTLESSNESS; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STRESS; SUICIDE; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 26244458417     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2005.03.008     Document Type: Article

References (43)

1. S.E. Starkstein M. Merello Psychiatric and Cognitive disorders in Parkinson's disease 2002 Cambridge University Cambridge 142 160
2. J.R. Slaughter, K.A. Slaughter, D. Nichols, S.E. Holmes, and M.P. Mortens Prevalence, clinical manifestations, etiology and treatment of depression in Parkinson's disease J Neuropsychiatry Clin Neurosci 13 2001 87 96
3. C.W. Olanow, R.L. Watts, and W.C. Coller An algorithm for the management of Parkinson's Disease Neurology 56 Suppl. 5 2001 S1 S88
4. I. Hegeman-Richard, R. Kurlan Parkinson's Study group A survey of antidepressant use in Parkinson's disease Neurology 49 1997 1168 1170
5. A. Liberman The management of neuropsychiatric symptoms of Parkinson's disease Neurology 50 Suppl. 6 1998 S33 S38
6. D.J. Brooks, and M. Doder Depression in Parkinson's Disease Current Opinion in Neurology 14 2001 465 470
7. G.N. Shabnam, C. Th, D.H.R. Kho, and C. Ce Therapies for depression in Parkinson's disease Cochrane Database Syst Rev 3 2003
8. T.H. Chung, K.H.O. Deane, S. Ghazi-Noori, H. Rickards, and C.E. Clarke Systematic review of antidepressant therapies in Parkinson's disease Cochrane Database, Parkinsonism and related disorders 10 2003 59 65
9. E. Sanders-Bush, and S.E. Mayer 5HT receptor agonists and antagonists J.G. Hardman L.E. Limbird Goodman & Gilman's: The pharmacological basis of the therapeutics 2001 McGraw Hill 269 290
10. J.E. Kelsey, and C.B. Nemeroff Selective serotonin reuptake inhibitors A. Sadock V. Sadock Comprehensive textbook of psychiatry 2000 Lippincott & Williams 2432 2454
11. E.H. Heinonen, and V. Myllyla Safety of selegeline (Deprenyl) in the treatment of Parkinson's disease Drug saf 19 1 1998 11 22
12. C.F. Caley Extrapyramidal reactions and selective serotonin receptor uptake inhibitors Ann Psychopharmacother 31 1997 1481 1489
13. R.M. Lane SSRI-induced extrapyramidal side effects and akathisia: implications for treatment J Psychopharmacology 13 1998 192 214
14. W.J. Burke, I. Gergel, and A. Bose Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients J Clin Psych 63 2002 331 336
15. E.N.H. Jansen Steur Increase in Parkinson's disability after fluoxetine medication Neurology 43 1993 211 213
16. A. Herve, S.T. Schuck, and N. Manduit Depression in Parkinson's disease Brit Med J 320 2000 1287 1288
17. G.J.R. Masterton The pros and cons of SSRI antidepressants Coll Physicians Edinb 33 2003 162 167
18. J.S. Olver, G.D. Burrows, and T.R. Norman Third generation antidepressants Curr Therap 43 2002 7 13
19. L. Wermuth, P.S. Sorensen, B. Timm, N.P. Utzon, J. Boas, E. Dupont, I. Magnussen, B. Mikkelsen, J. Worm-Petersen, L. Lauritzen, L. Bayer, and P. Bech Depression in idiopathic Parkinson's disease treated with citalopram-A placebo-controlled trial Nordic Journal of Psychiatry 52 1998 163 169
20. S. Norman, A.I. Troster, J.A. Fields, and R. Brooks Effects of depression and Parkinson's disease on cognitive functioning J Neuropsychiatry Clin Neurosci 14 1 2002 31 36
21. W. Poewe, and K. Seppi Treatment options for depression and psychosis in Parkinson's Disease J Neurol 248 Suppl. 3 2001 12 21
22. R.A. Hauser, and T.A. Zesiewicz Sertraline for the treatment of depression in Parkinson's disease Mov Disord 12 1997 756 759
23. I.H. Richard, and R. Kurlan A survey of antidepressant drug use in Parkinson's disease. (Parkinson study group) Neurology 49 1997 1168 1170
24. T. Klaassenn, F.R.J. Verhey, G.H.J.M. Sneijders, H.C.W. de Vet, and H.M. van Praag Treatment of depression in Parkinson's disease: a meta-analysis The Journal of Neuropsychiatry and Clinical Neurosciences 7 1995 281 286
25. J.L. Cummings, and D.L. Mastermann Depression in patients with PD Int J Geriatr Psychiatry Sep. 14 1999 711 718
26. J. Andersen, E. Aabro, N. Gulmann, A. Hjelmsted, and H.E. Pedersen Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA Acta Neurol Scand 62 1980 210 219
27. J.M. Rabey, E. Orlov, and A.D. Korczyn Comparison of Fluvoxamine versus Amitriptyline for treatment of depression in Parkinson's disease Neurology 46 1996 A374
28. M. Serrano-Duenas A comparison between low doses of amytriptyline and low doses of fluoxitine used in the control of depression in patients suffering from Parkinson's disease Rev Neurol 15 2002 1010 1014
29. M.H. Corrigan, A.Q. Denahan, C.E. Wright, R.J. Ragual, and D.L. Evans Comparison of pramipexole, fluoxetine, and placebo in patients with major depression Depress Anxiety 11 2000 58 65
30. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J, Klajblova H, Kulist'ak P, Ressner P, Svatova J, Urbanek K, Veliskova J. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003 Jul; 10(4): 399-406.
31. B. Fulton, and P. Banfield Moclobemide: an update of its pharmacological property and therapeutic Drugs 52 1996 450 474
32. A.F. Leentjens, F.R. Verly, and F.W. Vreeling Successful treatment of depression in a Parkinsonian patient with bupropion Ned Tijdsch Geneeskd 144 45 2000 2157 2159
33. C. Normann, B. Hesslinger, M. Frameknecht Berger, and J. Walder Psychosis during chronic levodopa therapy triggered by the antidepressant drug mirtazapine Pharmacopsychotherapy 30 1997 263 265
34. M.R. Lemke Effects of reboxetine on depression in Parkinson's disease J Cli Psychiatry 6314 2002 300 304
35. A. Khan, S. Khan, and R. Kolts Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports M. J. Psychiatr 160 2003 790 792
36. M.S. Okun, and R.L. Watts Clinical features and treatment of depression associated with Parkinson's disease Neurology 58 Suppl. 1 2002 63 70
37. van de Vijver, R.A. Roos, P.A. Jansen, S.J. Parsius, and A. de Boer The start of an selective serotonin receptor uptake inhibitor (SSRI) and increase in antiparkinsonian drug treatment in patients on levodopa Br. J. Clin. Pharmac. 54 2 2002 168 170
38. G. Linazasoro Worsening of Parkinson's disease by citalopram Parkinsonism Related Disorders 6 2000 111 113
39. I. Rampello, S. Chiechio, R. Raffaele, I. Vecchio, and F. Nicholetti The SSRI citalopram improved bradykinesia in patients with Parkinson's Disease treated with L-dopa Clin Neuropharmacol 25 2002 21 24
40. P.G. Gerber, and L.D. Lynd Selective serotonin reuptake inhibitor- induced movement disorders. Ann Pharmacother 32 1998 692 698
41. G. Dell'Agnello, R. Cearvollo, A. Nuti, G. Bellini, A. Piccino, C. D'Avino, L. Dell'Osso, and U. Bonacello SSRIs do not worsen Parkinson's disease. Evidence from an open-label prospective study Clin Neuropharmacol 24 2001 221 227
42. S. Tesei, A. Antonini, M. canesi, A. Zecchinelli, C.B. Mariani, and G. Pezzoli Tolerability of paroxetine in the Parkinson's disease: a prospective study Mov Disord 15 2000 989
43. C.F. Caley, and J.H. Friedman Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53 1992 278 282